About Us

Plexxikon was founded in 2001 by a team of biotech visionaries Joseph Schlessinger, Sung-Hou Kim, K. Peter Hirth, and Thomas R. Kassberg, with the goal of accelerating drug discovery with high throughput crystallography. By focusing on genetic mutations that drive disease proliferation, Plexxikon has earned a reputation as a leader in targeted drug discovery and translational, personalized medicine. With both drug discovery and early drug development conducted in-house, Plexxikon has:

  • Invented Zelboraf® (partnered with Roche)
  • Invented Turalio® (partnered with Daiichi Sankyo)
  • Introduced 8 other drug candidates into clinical trials

In 2011, Plexxikon was acquired by the Daiichi Sankyo Group, and continues to build its diverse pipeline of personalized drugs.

plexxikon scaffold-based drug design image

Leadership Team

Photo of Gideon E. Bollag, Ph.D.

Chief Executive Officer

Photo of Chao Zhang, Ph.D.

Chief Scientific Officer

Photo of Marguerite Hutinson JD.

Senior Vice President & General Counsel

Photo of Jackie Walling, MBChB, Ph.D.

Consulting Chief Medical Officer

Photo of Wayne Spevak, Ph.D.

Vice President, Chemistry

Photo of Athanasios Tsiatis

Vice President, Clinical Development

Photo of Jason Halladay, Ph.D.

Vice President, Nonclinical Development